Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Director · CEO | February 02, 2026 | February 06, 2026 |
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date February 02, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 274,800 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 274,800 · Balance 274,800 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2036-02-01 | Direct | 961,700 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 961,700 · Balance 961,700 F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
Aldeyra Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 70,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 70,000 · Balance 70,000 F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2036-06-08 | Direct | 3,318 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 3,318 · Balance 3,318 F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
F2: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2026 Filed Jun 11, 2026 20:21 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 3,318 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267605 · ownership.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,318 Underlying: Common Stock · 3,318 shares Expires 2036-06-08 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 20:21 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0001193125-26-267605 · ownership.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-06-08 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 63,475 | $0.00 | $0.00 |
DisclosureSEC source: 0001604457-26-000005 · form4-02052026_090254.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,425 Underlying: Common Stock · 63,475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 18,611 | $3.47 | $64,580.17 |
DisclosureSEC source: 0001604457-26-000005 · form4-02052026_090254.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,543,886 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:45 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 63,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001604457-26-000005 · form4-02052026_090254.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,562,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 02, 2026 Filed Feb 6, 2026 23:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 961,700 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001604457-26-000007 · form4-02062026_110224.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 961,700 Underlying: Common Stock · 961,700 shares Expires 2036-02-01 F3 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 02, 2026 Filed Feb 6, 2026 23:10 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 274,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001604457-26-000007 · form4-02062026_110224.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,800 Underlying: Common Stock · 274,800 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F2 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:32 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 29,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001604457-26-000003 · form4-01052026_090114.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,034 Underlying: Common Stock · 29,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:32 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 9,952 | $2.88 | $28,661.76 |
DisclosureSEC source: 0001604457-26-000003 · form4-01052026_090114.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,499,022 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:32 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 29,150 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001604457-26-000003 · form4-01052026_090114.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,508,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:36 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 2,413 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085489 · ownership.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,413 Underlying: Common Stock · 2,413 shares Expires 2035-06-09 F2 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:36 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantStock Option (Right to Buy) · Derivative | 62,728 | $0.00 Strike: $2.69 | $0.00 |
DisclosureSEC source: 0000950170-25-085489 · ownership.xml · derivative · entry 1 Walker Neal · CIK 0001604457 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,728 Underlying: Common Stock · 62,728 shares Expires 2035-06-09 F1 · derivative.exercise_date: Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011955 · form4-05052025_040501.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,975 | $1.38 | $4,105.50 |
DisclosureSEC source: 0001415889-25-011955 · form4-05052025_040501.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,479,824 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-011955 · form4-05052025_040501.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,482,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-009937 · form4-04032025_040410.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,467 Underlying: Common Stock · 9,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,042 | $1.48 | $4,502.16 |
DisclosureSEC source: 0001415889-25-009937 · form4-04032025_040410.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,473,332 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-009937 · form4-04032025_040410.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,476,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006496 · form4-03042025_040312.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,934 Underlying: Common Stock · 9,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning March 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,277 | $1.99 | $6,521.23 |
DisclosureSEC source: 0001415889-25-006496 · form4-03042025_040312.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,466,907 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-006496 · form4-03042025_040312.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,470,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 888,800 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001415889-25-002941 · form4-02042025_040208.xml · derivative · entry 5 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 888,800 Underlying: Common Stock · 888,800 shares Expires 2035-02-02 F5 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 253,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002941 · form4-02042025_040208.xml · derivative · entry 4 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,900 Underlying: Common Stock · 253,900 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 3, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002941 · form4-02042025_040208.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,400 Underlying: Common Stock · 9,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,559 | $2.48 | $8,826.32 |
DisclosureSEC source: 0001415889-25-002941 · form4-02042025_040208.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,460,718 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002941 · form4-02042025_040208.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,464,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 29,149 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000621 · form4-01032025_060101.xml · derivative · entry 7 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,184 Underlying: Common Stock · 29,149 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 88,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000621 · form4-01032025_060101.xml · derivative · entry 6 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,333 Underlying: Common Stock · 88,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. F4 · derivative.expiration_date: The shares underlying these restricted stock units vest as to 33% on January 2, 2025, 33% on January 2, 2026, and 34% on January 2, 2027, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 13,532 | $2.48 | $33,559.36 |
DisclosureSEC source: 0001415889-25-000621 · form4-01032025_060101.xml · nonDerivative · entry 4 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,454,810 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 29,149 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000621 · form4-01032025_060101.xml · nonDerivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,468,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-000621 · form4-01032025_060101.xml · derivative · entry 5 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,867 Underlying: Common Stock · 9,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 3,904 | $2.48 | $9,681.92 |
DisclosureSEC source: 0001415889-25-000621 · form4-01032025_060101.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,439,193 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 23:25 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-000621 · form4-01032025_060101.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,443,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 118,840 | $0.00 Strike: $1.52 | $0.00 |
DisclosureSEC source: 0001415889-24-028466 · form4-12062024_041206.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 118,840 shares Expires 2024-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 68,343 | $3.76 | $256,969.68 |
DisclosureSEC source: 0001415889-24-028466 · form4-12062024_041206.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,433,630 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the exercise price and the Reporting Person's tax withholding obligations in connection with the option exercise described in this Form 4. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 118,840 | $1.52 | $180,636.80 |
DisclosureSEC source: 0001415889-24-028466 · form4-12062024_041206.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,501,973 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-028074 · form4-12032024_041203.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,334 Underlying: Common Stock · 9,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,721 | $4.07 | $11,074.47 |
DisclosureSEC source: 0001415889-24-028074 · form4-12032024_041203.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,383,133 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| December 01, 2024 Filed Dec 3, 2024 21:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-028074 · form4-12032024_041203.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,385,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-026138 · form4-11052024_041101.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,800 Underlying: Common Stock · 9,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,721 | $2.09 | $5,686.89 |
DisclosureSEC source: 0001415889-24-026138 · form4-11052024_041101.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,376,388 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-026138 · form4-11052024_041101.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,379,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,467 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-024608 · form4-10032024_041004.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,267 Underlying: Common Stock · 9,467 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,722 | $1.18 | $3,211.96 |
DisclosureSEC source: 0001415889-24-024608 · form4-10032024_041004.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,369,642 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-024608 · form4-10032024_041004.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,372,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 21:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionRestricted Stock Units · Derivative | 9,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022794 · form4-09042024_080935.xml · derivative · entry 3 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,734 Underlying: Common Stock · 9,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F3 · derivative.exercise_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. F3 · derivative.expiration_date: The shares vest in equal monthly installments over 15 months beginning February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as the Interim CEO to the Company as of each such vesting date, provided that in the event he ceases to be Interim CEO but continues to provide Continuous Service in any capacity, such awards will continue to vest in the event that the Issuer's Board of Directors determines in its sole discretion that he achieved the Performance Goals (as defined in his letter agreement of employment as Interim CEO) prior to the cessation of his employment as Interim CEO. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 21:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Tax withholdingCommon Stock | 2,722 | $1.18 | $3,211.96 |
DisclosureSEC source: 0001415889-24-022794 · form4-09042024_080935.xml · nonDerivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,362,897 F2 · kind: The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 21:08 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 9,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022794 · form4-09042024_080935.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,365,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 43,548 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001415889-24-021154 · form4-08132024_040801.xml · derivative · entry 2 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,548 shares Expires 2024-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested and exercisable. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 20:15 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 43,548 | $0.72 | $31,354.56 |
DisclosureSEC source: 0001415889-24-021154 · form4-08132024_040801.xml · nonDerivative · entry 1 Walker Neal · CIK 0001604457 · Director · INTERIM PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,356,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.